Indivior PLC announced that the FDA approved Opvee (nalmefene) nasal spray from Opiant Pharma /Invidor, for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression
Zealand Pharma announced that the FDA has accepted for filing the company’s New Drug Application (NDA) for the HypoPal Rescue Pen (dasiglucagon) for the treatment of hypoglycemia in people with diabetes.
24-week, randomized, double blind, placebo-controlled trial to evaluate safety and efficacy of canagliflozin as compared with placebo in reducing the...
The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade...
Flexion Therapeutics, Inc. announced that a pooled analysis of data from three Phase II/III randomized clinical trials on the use...
Acacia Pharma Group plc announced that data and analyses from its positive Phase III clinical trial of Barhemsys (intravenous amisulpride)...
The loss of motor neurons (MNs) is a hallmark of the neuromuscular disease spinal muscular atrophy (SMA); however, it is unclear whether this phenotype autonomously originates within the MN. To address this question...
Orexo AB (publ.), announces the submission of a New Drug Application (NDA) to the FDA for its lead pharmaceutical pipeline asset, OX 124, a nasal rescue medication for opioid overdose.
Zealand Pharma A/S presented elaborated results from two Phase III clinical studies with dasiglucagon as treatment for severe hypoglycemia as well as one preclinical PK/PD study investigating aqueous versus DMSO formulations of glucagon and the pharmacodynamics of dasiglucagon in aqueous solution at the 80th Scientific Sessions of the American Diabetes Association (ADA) held as a virtual meeting June 12-16, 2020.